



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	What should be the future direction of development in the field of prostate cancer with lung metastasis?	1
ABSTRACT			
Structured summary	2	The structured abstract includes BACKGROUND, AIMS, METHODS, RESULTS and CONCLUSION.	2-3
INTRODUCTION			
Rationale	3	Described in the INTRODUCTION.	4-5
Objectives	4	Described in the INTRODUCTION.	4-5
METHODS			
Protocol and registration	5	The protocol and registration do not apply.	
Eligibility criteria	6	Described in the <i>Collection of PCLM Paper Data</i> .	5-6
Information sources	7	Described in the <i>Collection of PCLM Paper Data</i> .	5-6
Search	8	Described in the <i>Collection of PCLM Paper Data</i> .	5-6
Study selection	9	Described in the <i>Collection of PCLM Paper Data</i> .	5-6
Data collection process	10	Described in the <i>Collection of PCLM Paper Data</i> .	5-6
Data items	11	Described in the <i>Collection of PCLM Paper Data</i> .	5-6
Risk of bias in individual studies	12	There is no risk of bias in individual studies.	
Summary measures	13	Described in the <i>Exploration of Molecular Mechanisms in PCLM</i> .	6
Synthesis of results	14	Described in the <i>Exploration of Molecular Mechanisms in PCLM</i> .	6



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	There is no assessment of the risk of bias that may affect the cumulative evidence.	
Additional analyses	16	There are no additional analyses.	
RESULTS			
Study selection	17	Described in the <i>Collection of PCLM Paper Data</i> and Figure 1.	5-6
Study characteristics	18	Described in the part of RESULTS and in the tables mentioned.	7-10
Risk of bias within studies	19	There is no risk of bias in studies.	
Results of individual studies	20	There are no results of individual studies.	
Synthesis of results	21	Described in the part of RESULTS and the figures mentioned.	7-10
Risk of bias across studies	22	There is no assessment of the risk of bias across studies.	
Additional analysis	23	There is no additional analysis.	
DISCUSSION			
Summary of evidence	24	Described in the part of DISCUSSION.	10-21
Limitations	25	Described in the Limitation of this Study and Future Work Plans.	22
Conclusions	26	Described in the CONCLUSION.	22-23
FUNDING			
Funding	27	Described in the manuscript and more details in the 87273-Approved Grant Application Form(s) or Funding Agency Copy of any Approval Documents.	

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.